A European Outlook: Gastroenterology

What happens when funding surges, pipelines expand, but talent supply tightens?

Gastroenterology is entering a critical phase in 2025. With €11.1B in investment and several first-in-class drug launches on the horizon, the opportunity is clear—but so are the pressures. From R&D pipelines to talent pipelines, this report outlines what’s moving, what’s missing, and where biotech leaders should focus next.

What you’ll learn in this report:

• Where demand is outpacing supply – Discover why hiring GI specialists is becoming more competitive, and what companies can do to attract them.
• What’s launching next – A breakdown of five new therapies projected to generate €14.44B in combined peak sales by 2030.
• Where the funding is going – Insights into €3.6B in Q1 2025 VC activity and the biotechs making the biggest moves in GI.
• Which innovations are worth watching – From microbiome therapies to novel biologics, get a preview of first-in-class assets in development.
• How geography is shaping strategy – A look at Europe’s IBD and IBS patient clusters—and how they influence hiring and clinical planning.

Read the full report to stay ahead of the curve.